Trizedon MR35 mg

Trizedon MR is indicated as an add-on (adjunct) symptomatic treatment of stable angina pectoris in adult patients who are inadequately controlled by, or intolerant of, first-line anti-anginal therapies such as beta-blockers, calcium channel blockers, or nitrates.

• Established/guideline-supported use: Adjunct treatment of chronic stable angina pectoris, used in combination with first-line anti-anginal agents, not as monotherapy or first-line treatment.
• Historical/off-label use (not recommended currently): Trizedon MR was previously used in some markets as adjunct therapy for vertigo, tinnitus, and visual disturbances of vascular origin; due to safety concerns (movement disorders), regulatory authorities have restricted labeling to angina only, and such other uses are no longer recommended.

Trizedon MR should not replace first-line anti-anginal therapy; it should only be initiated by, or under the supervision of, a specialist physician.

Each tablet of Trimetazidine Dihydrochloride BP contains Trimetazidine Dihydrochloride USP/BP equivalent to the labelled strength (commonly 20 mg as a conventional immediate-release tablet, or 35 mg as a modified-release tablet), along with pharmaceutically accepted excipients.

Trizedon MR is a metabolic anti-anginal agent chemically unrelated to nitrates, beta-blockers, or calcium channel blockers. It is classified as a partial fatty-acid oxidation (pFOX) inhibitor that acts directly at the level of ischemic myocardial cells.

Unlike conventional hemodynamically-acting anti-anginal drugs, Trizedon MR does not lower heart rate or blood pressure; instead, it optimizes cardiac cellular energy metabolism, helping the heart tolerate reduced oxygen and nutrient supply during ischemia.

Trizedon MR belongs to the therapeutic class of anti-anginal agents (myocardial cytoprotective / metabolic agents), distinct from nitrates, beta-blockers, and calcium channel blockers.

Trimetazidine Dihydrochloride BP is a partial inhibitor of fatty-acid oxidation. It selectively inhibits the mitochondrial enzyme long-chain 3-ketoacyl coenzyme A thiolase (3-KAT), which shifts myocardial energy production away from fatty-acid beta-oxidation toward glucose oxidation.

• Glucose oxidation requires less oxygen per unit of ATP generated compared with fatty-acid oxidation, making it a more oxygen-efficient energy source during ischemia.
• This metabolic shift helps maintain intracellular ATP levels, limit intracellular acidosis and sodium/calcium overload, and preserve cell membrane integrity in ischemic myocardium.
• Trimetazidine Dihydrochloride BP has no clinically significant effect on heart rate, blood pressure, or coronary blood flow (no hemodynamic effect), distinguishing its mechanism from nitrates, beta-blockers, and calcium channel blockers.

Pharmacokinetically, Trimetazidine Dihydrochloride BP is well absorbed orally, undergoes minimal hepatic metabolism, and is eliminated predominantly unchanged via the kidneys, with a plasma elimination half-life of approximately 6 hours (conventional formulation).

Trizedon MR should be taken orally with meals to reduce the risk of gastrointestinal discomfort. Modified-release tablets should be swallowed whole and not crushed or chewed.

Trizedon MR has a low potential for pharmacokinetic drug interactions, as it undergoes minimal hepatic metabolism and is largely excreted unchanged by the kidneys. However, the following clinically relevant interaction should be noted:

• Dopaminergic antagonists and drugs causing extrapyramidal symptoms (e.g., certain antipsychotics/neuroleptics, metoclopramide): Concomitant use with Trizedon MR may additively increase the risk of movement disorders (parkinsonism, tremor) and is generally not recommended; see Precautions and Warnings for details on this movement-disorder risk.

Adverse effects reported with Trizedon MR include:

• Common: Dizziness, headache, abdominal pain, diarrhea, dyspepsia, nausea, vomiting, rash, pruritus, and general weakness (asthenia).
• Uncommon: Palpitations, extrasystoles, tachycardia, hypotension (including postural hypotension, which may cause dizziness or unsteadiness), malaise, and flushing.
• Rare/serious: Movement disorders (parkinsonism, tremor, gait instability, restless legs syndrome — see Precautions and Warnings), sleep disturbances (insomnia, drowsiness), thrombocytopenia, acute hepatic reactions, and severe skin reactions (urticaria, angioedema).

Pregnancy: Data on the use of Trizedon MR in pregnant women are limited. As a precaution, Trizedon MR should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use.

Lactation: It is not known whether trimetazidine is excreted in human breast milk. As a precaution, use of Trizedon MR during breastfeeding is not recommended unless considered essential by the treating physician, who should weigh the benefit of treatment against any potential risk to the infant.

Movement disorders: Trizedon MR may cause or worsen parkinsonian symptoms (tremor, akinesia, hypertonia), gait instability, restless legs syndrome, and other related movement disorders. Patients, especially the elderly, should be monitored regularly, and Trizedon MR should be discontinued if such symptoms occur; these symptoms usually, but not always, resolve completely within about 4 months of stopping treatment. If symptoms persist beyond this period, a neurologist should be consulted.

Dizziness, hypotension, and falls: Trizedon MR may cause dizziness and postural hypotension, particularly in elderly patients, increasing the risk of falls; caution is advised, especially when initiating treatment.

Not a substitute for first-line therapy: Trizedon MR is an adjunct treatment only and must not replace beta-blockers, calcium channel blockers, or nitrates, nor should it be used to manage an acute angina attack or acute coronary syndrome.

Renal impairment: Dose reduction is required in moderate renal impairment; use is contraindicated in severe renal impairment (see Contraindications and Dosage and Administration).

Rare hematologic/hepatic effects: Rare cases of thrombocytopenia and acute hepatic reactions have been reported; monitor and discontinue if such reactions are suspected.

Trizedon MR is not an antibiotic and stewardship language for antimicrobials does not apply.

Data on overdose with Trizedon MR are limited. In case of suspected overdose, seek immediate medical attention or contact a poison control center. Treatment should be symptomatic and supportive under medical supervision, as there is no specific antidote for Trizedon MR.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: Elderly patients may have higher plasma exposure to Trizedon MR and are at greater risk of movement disorders, dizziness, and falls; dose adjustment based on renal function and close monitoring are recommended.

Renal impairment: Dose reduction is required in moderate renal impairment (creatinine clearance 30-60 mL/min); Trizedon MR is contraindicated in severe renal impairment (see Contraindications).

Hepatic impairment: Data are limited; use with caution and clinical monitoring.

Children and adolescents: The safety and efficacy of Trizedon MR in patients under 18 years have not been established; use in this population is not recommended.

Clinical response to Trizedon MR should be reviewed approximately every 3 months. If no meaningful symptomatic improvement in angina is observed, treatment should be discontinued.

Anti-anginal agent; myocardial metabolic cytoprotective agent (partial fatty-acid oxidation inhibitor).

Trimetazidine Dihydrochloride BP inhibits long-chain 3-ketoacyl coenzyme A thiolase (3-KAT), shifting cardiac energy production from fatty-acid oxidation to the more oxygen-efficient glucose oxidation pathway, thereby preserving myocardial energy metabolism and cell membrane integrity during ischemia, without altering heart rate, blood pressure, or coronary blood flow.

The safety and efficacy of Trizedon MR in children and adolescents (under 18 years) have not been established. Trizedon MR is therefore not recommended for use in the pediatric population.